Enteric coated, soluble creatine and polyethylene glycol composition for enhanced skeletal uptake of oral creatine

Abstract

An oral creatine formulation includes soluble creatine and polyethylene glycol, coated with an enteric coating. The most preferred soluble creatine is creatine HCl. The most preferred polyethylene glycols have an average molecular weight of from 3150 to 3685, although for particular formulation formulations and particular uses, the average molecular weight polyethylene glycols may range from 190 to 9000.

1 . A oral creatine formulation comprising:
 creatine hydrochloride; and   polyethylene glycol,   wherein the creatine hydrochloride and polyethylene glycol are coated with an enteric coating.   
   
   
       2 . The creatine formulation of  claim 1 , wherein the polyethylene glycol has an average molecular weight of from 3150 to 3685. 
   
   
       3 . The creatine formulation of  claim 1 , wherein the polyethylene glycol has an average molecular weight of from 3600 to 4400. 
   
   
       4 . The creatine formulation of  claim 1 , wherein the polyethylene glycol has an average molecular weight of from 4400 to 4800 
   
   
       5 . The creatine formulation of  claim 1 , wherein a dosage of the formulation is from 0.1 to 10 grams per day of creatine equivalents. 
   
   
       6 . The creatine formulation of  claim 2 , wherein a dosage of the formulation is from 0.1 to 10 grams per day of creatine equivalents. 
   
   
       7 . The creatine formulation of  claim 3 , wherein a dosage of the formulation is from 0.1 to 10 grams per day of creatine equivalents. 
   
   
       8 . The creatine formulation of  claim 4  wherein a dosage of the formulation is from 0.1 to 10 grams per day of creatine equivalents. 
   
   
       9 . The creatine formulation of  claim 1 , wherein a dosage of the formulation is from 10 to 20 grams per day of creatine equivalents. 
   
   
       10 . The creatine formulation of  claim 2 , wherein a dosage of the formulation is from 10 to 20 grams per day of creatine equivalents. 
   
   
       11 . The creatine formulation of  claim 3 , wherein a dosage of the formulation is from 10 to 20 grams per day of creatine equivalents. 
   
   
       12 . The creatine formulation of  claim 4  wherein a dosage of the formulation is from 10 to 20 grams per day of creatine equivalents. 
   
   
       13 . The creatine formulation of  claim 1 , wherein the formulation after ingestion, is effective to relieve, minimize or prevent symptoms of Parkinson's disease. 
   
   
       14 . The creatine formulation of  claim 1 , wherein the formulation after ingestion, is effective to relieve, minimize or prevent symptoms of a muscle-wasting disease or condition. 
   
   
       15 . A method of supplementing a mammal's creatine stores comprising providing a mixture of polyethylene glycol and a soluble creatine coated with an enteric coating and ingesting the coated creatine formulation. 
   
   
       16 . The method of  claim 15 , wherein the polyethylene glycol has an average molecular weight of from 3150 to 3685. 
   
   
       17 . The method of  claim 15 , wherein from 0.1 to 20 grams of the soluble creatine are ingested per day. 
   
   
       18 . The method of  claim 15 , wherein from 0.5 to 2 grams of the soluble creatine are ingested per day. 
   
   
       19 . A method of minimizing symptoms of a muscle-wasting disease or condition comprising providing a mixture of polyethylene glycol and a soluble creatine coated with an enteric coating and ingesting the coated creatine formulation. 
   
   
       20 . The method of  claim 19 , wherein the polyethylene glycol has an average molecular weight of from 3150 to 3685. 
   
   
       21 . The method of  claim 19 , wherein from 0.1 to 10 grams of the soluble creatine are ingested per day. 
   
   
       22 . The method of  claim 19 , wherein from 10 to 20 grams of the soluble creatine are ingested per day.